DRG at AACC: Primary Strengths
We sat down with the top executives and staff of DRG at the 2016 AACC Annual Meeting and asked them each about what DRG’s strengths are and how they add value to customers and business partners.
Wilhelm Saenger (full profile)
Our flexibility, flexibility and creating from an idea a new product and bringing it to the market. When we started at DRG, we were only a trading company. 26 years ago, we started our own production in September 1990. We developed a lot of ELISAS. Of course, 8 years ago we started this development of our hybrid, DRG Hybrid XL.
In the meantime, we adapted more than 25 assays onto the hybrid. This could be the future of DRG because this is an instrument here where we are running some niche parameters like Calprotectin, as I’ve heard from our general manager from Poland. He is very satisfied. This could be really a very interesting product. This is really the strength of DRG to bring ideas to a new product. We are well known in the whole world, and we are selling to a lot of companies. We have a lot of good customers included and that is our strength with DRG.
Michael Martini (full profile)
Leadership really is what sets us apart. It’s a solely owned company with the six subsidiaries, but really, the strength of DRG is our distribution. We distribute to about 110 different countries throughout the world, and that’s something that you really credit to Dr. G’s years worth of groundwork, and footwork, and going to meeting like this year after year, building relationships, alliances, and really building a distribution network that’s second to none.
Dr. Witold Jurkiewicz (full profile)
You know, we are working very multi-nationally. We have offices in Germany, in Russia, in Poland, in Czech Republic, in China, and also here, headquartering New Jersey. We are a multi-product company. We are selling our developed kits. Also, we are distribution company. We are working from the many, many years with distribution of medical devices, medical instruments, mostly for cardiology, cardiac surgery. Everything together make us strong partner and strong company all over the world.
DRG is a multi-cultural company. We have Russians, we have Ukrainians, we have Italians, half-Italians. This is important. Culture, and history, and a diversity means more ideas, more innovation. This is very important and this is what pushes the products. For me, it’s important.
Dr. Oleg Vishnevski
The team, of course. The group of people who make it happen. The knowledge. We employ really prominent guys who’s developing their agents, who’s developing the kids, who is involved in the hardware, and of course, in the sales.
Dr. Cyril E. Geacintov (full profile)
The primary strength of DRG, of course, the people of DRG. The fact that we’re an international company is very easily observable when you look at our office. The other thing is that as a result of this, we have built up a very strong international presence. There are actually only 196 countries in the world announced, and we sell in 120 of them. We have the reach, the international reach, and we have the scientific background. We have the staff, multi-lingual, and we have penetration of markets worldwide. That’s at least some of the things that we do that are great.
Latest posts by Gregory C. Guest (see all)
- DRG distributor “SERION-BRAZIL” successfully attends Brazilian Laboratory Medicine Exhibition in Sao Paulo, Brazil - November 22, 2017
- HYBRiD-XL Launch NEWS: DRG is expanding the test menu with TM-CA 72-4! - November 8, 2017
- DRG´s Newly Optimized Salivary Testosterone Kit used in New Study! - September 18, 2017
News and Updates
DRG distributor “SERION-BRAZIL” successfully attends Brazilian Laboratory Medicine Exhibition in Sao Paulo, Brazil
DRG is proud to announce the new partnership with Serion-Brazil and looks forward to a longstanding and successful business relationship! Mr. Gustavo Ruales, DRG International's Latin American Sales Manager, also attended the exhibition to support...read more
We are proud to announce the launch of a new assays for DRG:HYBRiD-XL®: TM-CA 72-4. Clinical Application: Tumor Marker (gastrointestinal cancer) Tumor Marker (ovarian cancer) CA 72‑4 is the marker of choice for the therapeutic monitoring and follow-up...read more
New Poster presented using DRG´s newly optimized Salivary Testosterone Kit Ellie Shuo Jin, Doctoral Candidate in Clinical Psychology of the University of Texas at Austin, presented her poster at the Meeting of International Society of Psychoneuroendocrinology...read more
DRG is proud to announce that our TM-CA 72-4 ELISA Kit (EIA-5071) has been used in a recent cancer study done by NYU Winthrop Hospital. The DRG TM-CA 72-4 ELISA Kit is for sale in the United States as an RUO product and is CE marked for global sales. Please see...read more
DRG International, Inc., the authorized distributor for CHROMagar, recently attended the 2017 ASM Microbe General Meeting of the American Society for Microbiology in New Orleans, LA from June 1, 2017 – June 4, 2017. Attendees (pictured above, l to r) were Mr. Alberto...read more
Dear Customers, Suppliers, and Friends, We regret to inform you that Dr. Cyril E. Geacintov passed away on Tuesday, May 23. His death was sudden and unexpected. In his usual driven style he was working in the office until a few days ago and challenging his team on how...read more
DRG International, inc. recently launched our brand new Ecommerce site for USA customers! Click here to shop over 180 ELISA, Salivary ELISA, and CHROMagar products now: https://store.drg-international.com/ The Ecommerce store has over 180 products that are FDA...read more
DRG Booth with Visitors. From Left: Mr. Gideon Lim; Dr. Cyril E. Geacintov, CEO & Founder of DRG; Dr.Aw Tar Choon, MD at Changi General Hospital in Singapore; Mrs. Josephine Teo; Mrs. Elke Geacintov; Mr. Wilhelm Sanger. We are pleased to announce that the DRG...read more
DRG’s CA 72-4 ELISA Kit (EIA-5071), which uses antibodies licensed from the NIH, has been used in a recent study conducted by Winthrop University. The study used the DRG CA 72-4 ELISA Kit (EIA-5071) to explore the expression of CA72-4 compared to current FDA-approved...read more
DRG is pleased to officially announce that we are going to Medlab Dubai from February 6th-February 9th, 2017 at the Dubai International Convention & Exhibition Centre, attended by over 10,000 delegates. The conference features 11 CME-accredited conference...read more
We sat down with the top executives and staff of DRG at the 2016 AACC Annual Meeting and asked them questions about what makes them the worldwide leader in diagnostics. These are the key takeaways the top executives at DRG want you to remember. Michael Martini (full...read more
DRG’s staff is diverse and the company maintains a global presence requiring its staff to speak multiple languages as well as travel the world visiting DRG’s many offices and events. We sat down with the top executives and staff of DRG at the 2016 AACC Annual Meeting...read more